Author

D.-Y. Kim

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. D. Sung· 1 shared A.-R. Jang· 1 shared B.-G. Choi· 1 shared C. B. DeStefano· 1 shared C. Lai· 1 shared C. S. Hourigan· 1 shared D. Rizzieri· 1 shared G. W. Roloff· 1 shared

Activity by Year

2018-2019 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. D. Sung

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Unveiling the crucial role of type IV secretion system and motility of Helicobacter pylori in IL-1β production via NLRP3 inflammasome activation in neutrophils

A.-R. Jang, M.-J. Kang, J.-I. Shin, S.-W. Kwon, J.-Y. Park, J.-H. Ahn, T.-S. Lee, D.-Y. Kim, B.-G. Choi, M.-W. Seo, S.-J. Yang, M.-K. Shin, J.-H. Park

This study identifies host and bacterial factors, including TLR2, NLRP3 inflammasome, type IV secretion system, and bacterial motility, essential for H. pylori-induced IL-1β production in neutrophils.

bioRxiv · Aug 13, 2019Immunology

Molecular measurable residual disease testing of blood during AML cytotoxic therapy for early prediction of clinical response

H. Y. Wong, A. D. Sung, K. E. Lindblad, S. Sheela, G. W. Roloff, D. Rizzieri, M. Goswami, M. P. Mule, N. R. Ramos, J. Tang, J. Thompson, C. B. DeStefano, K. Romero, L. W. Dillon, D.-Y. Kim, , C. S. Hourigan

This study evaluates molecular residual disease in AML patients during chemotherapy, finding stable variant allele frequencies that may indicate limited therapeutic response.

bioRxiv · Sep 20, 2018Cancer Biology